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Background
Keratoconjunctivitis (KC) is an eye disease that poten-
tially leads to blindness if not treated properly, which
often requires follow-up for more than an expert. The
aim of this study is to evaluate the response of topical
tacrolimus in allergic keratoconjunctivitis.
Methods
A longitudinal study of series of cases conducted between
September/2013 and June/2014, with 24 patients followed
in Ocular Allergy ambulatory, Hospital das Clinicas of the
Federal University of Pernambuco. The patients included
in the study had symptoms such as: itching, burning, red-
ness and/or edema uncontrolled medical monitoring
initial and were then taken to the ophthalmologist for
defining more specific treatment.
Results
The median age was 10 years, with 15 male patients
(62%). Of the 24 patients, 14 (58%) patients had allergic
rhinitis, 7 (29%) had a diagnosis of asthma and rhinitis
associated and 2 (8%) had rhinitis, asthma and atopic
dermatitis. All were using medications for rhinitis and/
or asthma continuously. Regarding the treatment of
conjunctivitis, only 1 patient (4%) remitted symptoms
using of mast cell membrane stabilizer, 6 (25%) have
control of symptoms KC using mast cell membrane sta-
bilizer and antihistamine, others 6 (25 %) was necessary
to add an ocular lubricant. In 11 patients (46%) with
severe allergic KC was necessary to associate a topic
corticosteroids and 5 (45%) of these group became ster-
oid-dependent, only reaching remission of symptoms
with tacrolimus 0.03% ophthalmic ointment. All patients
who used tacrolimus reported improvement in signs and
symptoms and adverse events were limited to the local
burning in one patient who interrupted treatment,
despite that improvement of edema and hyperemia.
Conclusions
Allergic rhinitis is very common in patients with KC,
underscoring the importance of joint processing for
clinical improvement. The use of topical tacrolimus
0.03% in and out of the conjunctival sac seems to be in
the short term, effective, well tolerated and safe in the
treatment of allergic conjunctivitis refractory to tradi-
tional treatment, and avoid prolonged corticosteroid
therapy and its associated side effects, such as hyperten-
sion eyepiece.
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